News
Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
4h
Flow Space on MSNSemaglutide Is Not the Best GLP-1 Drug You Can Take for Losing Weight FastSemaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...
1d
CivicScience on MSNGLP-1 Trends by CivicScience: Access and Shortages, Desire for Customized Products, and Self-Care PreferencesDiscover more data.It’s safe to say that GLP-1 medications are becoming a household name. With 57% of Americans familiar with ...
Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...
DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today the results of a new data analysis on 102, ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...
GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
3d
Everyday Health on MSN9 Signs Your Compounded GLP-1 Supplier Is ShadySome online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results